Funds

ProFunds Biotechnology UltraSector Fund Investor Class

BIPIX

ProFunds Biotechnology UltraSector Fund Investor Class

Actions
  • Price (USD)65.33
  • Today's Change-0.13 / -0.20%
  • 1 Year change21.16%
Data delayed at least 15 minutes, as of Nov 17 2017.
More ▼

Total returns on $10,000

5Y
ProFunds Biotechnology UltraSector Inv
Fund
Trading--Leveraged Equity
Morningstar category
S&P 500 TR USD
Benchmark index

Profile and investment

Fund typeOpen Ended Investment Company
Investment style (stocks)Market Cap: Large
Investment Style: Growth
Morningstar categoryTrading--Leveraged Equity
Launch date19 Jun 2000
Price currencyUSD
DomicileUnited States
SymbolBIPIX
Manager & start date
Michael Neches
01 Oct 2013
Devin Sullivan
30 Sep 2016
Pricing frequencyDaily
Total net assets
323.82m USD
As of Oct 31 2017
Net expense ratio1.47%
Front end load--
Deferred load--
Redemption fee--
Min. initial investment15,000.00
USD
Min. additional investment--
Initial IRA--
Additional IRA--
Available for saleUnited States
More ▼

Top 5 holdings

Top 5 holdings as a per cent of portfolio
114.05%50.94%0.00%50.94%
Category average% Net assets% Short% Long
Company1 year changePortfolio weightLong allocation
Amgen Inc
AMGN:NSQ
+15.36%12.03%
AbbVie Inc
ABBV:NYQ
+51.72%10.42%
Celgene Corp
CELG:NSQ
-14.73%9.90%
Gilead Sciences Inc
GILD:NSQ
-4.15%9.31%
Soc 1.00% , 8/1/2017--9.28%
Per cent of portfolio in top 5 holdings: 50.94%
Top 10 Holdings

Diversification

Asset type

Asset type

US stock72.63%
Cash27.27%
Non-US stock0.00%
US bond0.00%
Non-US bond0.00%
Other0.09%

Top 5 sectors

Healthcare72.63%

Top 5 regions

United States72.63%
Sector and region weightings are calculated using only long position holdings of the portfolio.
The performance data shown in tables and graphs on this page is calculated in USD of the fund/index/average (as applicable), on a Bid To Bid / Nav to Nav basis, with gross dividends re-invested on ex-dividend date. Past performance is not necessarily a guide to future performance; unit prices may fall as well as rise.
All managed funds data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
All data shown on this page, unless noted otherwise is Data Source and Copyright: Morningstar, Inc. 2017
All Rights reserved
© 2017 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.
Pricing for ETFs is the latest price and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.